Aptose Upgraded to Trade on OTCQB Market
Aptose Biosciences (OTC: APTOF), a clinical-stage precision oncology company, announced its upgrade to the OTCQB Market effective July 1, 2025. The company, which develops tuspetinib (TUS) based triple drug frontline therapy for newly diagnosed acute myeloid leukemia (AML), will maintain its listing on the Toronto Stock Exchange (TSX) under the symbol "APS".
The OTCQB Venture Market caters to early-stage and developing U.S. and international companies that meet current reporting requirements and undergo annual verification and management certification processes.
Aptose Biosciences (OTC: APTOF), un'azienda di oncologia di precisione in fase clinica, ha annunciato il suo passaggio al mercato OTCQB a partire dal 1° luglio 2025. L'azienda, che sviluppa una terapia di prima linea a triplo farmaco a base di tuspetinib (TUS) per la leucemia mieloide acuta (AML) di nuova diagnosi, manterrà la sua quotazione alla Borsa di Toronto (TSX) con il simbolo "APS".
Il mercato OTCQB Venture è rivolto a società statunitensi e internazionali in fase iniziale e in crescita, che rispettano i requisiti di rendicontazione attuali e sottopongono a processi annuali di verifica e certificazione della gestione.
Aptose Biosciences (OTC: APTOF), una compañía de oncología de precisión en etapa clínica, anunció su ascenso al mercado OTCQB con efecto a partir del 1 de julio de 2025. La empresa, que desarrolla una terapia de primera línea con triple medicamento basada en tuspetinib (TUS) para la leucemia mieloide aguda (LMA) recién diagnosticada, mantendrá su cotización en la Bolsa de Valores de Toronto (TSX) bajo el símbolo "APS".
El mercado OTCQB Venture está dirigido a empresas estadounidenses e internacionales en etapas tempranas y en desarrollo que cumplen con los requisitos actuales de reporte y pasan por procesos anuales de verificación y certificación de gestión.
Aptose Biosciences (OTC: APTOF)는 임상 단계의 정밀 종양학 회사로서 2025년 7월 1일부로 OTCQB 시장으로의 상향 조정을 발표했습니다. 이 회사는 새로 진단된 급성 골수성 백혈병(AML)을 위한 tuspetinib(TUS) 기반의 3중 약물 1차 치료법을 개발하며, 토론토 증권거래소(TSX)에서는 "APS"라는 심볼로 계속 상장될 예정입니다.
OTCQB 벤처 시장은 현재 보고 요건을 충족하고 연례 검증 및 경영 인증 절차를 거치는 미국 및 국제 초기 단계 및 성장 중인 기업을 대상으로 합니다.
Aptose Biosciences (OTC : APTOF), une société d'oncologie de précision en phase clinique, a annoncé sa montée sur le marché OTCQB à compter du 1er juillet 2025. La société, qui développe une thérapie de première ligne à triple médicament basée sur le tuspetinib (TUS) pour la leucémie myéloïde aiguë (LMA) nouvellement diagnostiquée, conservera sa cotation à la Bourse de Toronto (TSX) sous le symbole "APS".
Le marché OTCQB Venture s'adresse aux entreprises américaines et internationales en phase de démarrage et en développement qui respectent les exigences actuelles de reporting et qui subissent des processus annuels de vérification et de certification de gestion.
Aptose Biosciences (OTC: APTOF), ein Unternehmen für präzisionsonkologische Therapien in der klinischen Phase, gab bekannt, dass es ab dem 1. Juli 2025 in den OTCQB-Markt aufsteigt. Das Unternehmen, das eine dreifach basierte Frontlinientherapie mit Tuspetinib (TUS) für neu diagnostizierte akute myeloische Leukämie (AML) entwickelt, wird weiterhin an der Toronto Stock Exchange (TSX) unter dem Symbol "APS" gelistet sein.
Der OTCQB Venture Market richtet sich an US-amerikanische und internationale Frühphasen- und Wachstumsunternehmen, die die aktuellen Berichtspflichten erfüllen und jährlichen Überprüfungs- sowie Managementzertifizierungsprozessen unterliegen.
- Upgraded listing status to OTCQB Market may provide increased visibility and accessibility for U.S. investors
- Maintains dual listing on TSX and OTCQB markets
- None.
Aptose will trade under the ticker symbol APTOF and begin trading on OTCQB today, July 1st
SAN DIEGO and TORONTO, July 01, 2025 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (TSX: APS; OTC: APTOF), a clinical-stage precision oncology company developing a tuspetinib (TUS) based triple drug frontline therapy to treat patients with newly diagnosed acute myeloid leukemia (AML), announced today that the Company has been upgraded to list for trading on the OTCQB Market under the ticker “APTOF,” in addition to the Company’s continued listing on the Toronto Stock Exchange (TSX) under the symbol “APS”. Trading on OTCQB begins today, July 1, 2025.
The OTCQB Venture Market is for early stage and developing U.S. and international companies. Companies are current in their reporting and undergo an annual verification and management certification process. Investors can find Real-Time quotes and market information for the company on www.otcmarkets.com.
About Aptose
Aptose Biosciences is a clinical-stage biotechnology company committed to developing precision medicines addressing unmet medical needs in oncology, with an initial focus on hematology. The Company’s lead clinical-stage, oral kinase inhibitor tuspetinib (TUS) has demonstrated activity as a monotherapy and in combination therapy in patients with relapsed or refractory acute myeloid leukemia (AML) and is being developed as a frontline triplet therapy in newly diagnosed AML. For more information, please visit www.aptose.com.
Forward Looking Statements
This press release may contain forward-looking statements within the meaning of Canadian and U.S. securities laws, including, but not limited to, statements relating to the Company’s plans, objectives, expectations and intentions and other statements including words such as “continue”, “expect”, “intend”, “will”, “should”, “would”, “may”, and other similar expressions. Such statements reflect our current views with respect to future events and are subject to risks and uncertainties and are necessarily based upon a number of estimates and assumptions that, while considered reasonable by us are inherently subject to significant business, economic, competitive, political and social uncertainties and contingencies. These risks and uncertainties include, among others: our ability to obtain the capital required for research and operations and to continue as a going concern; the inherent risks in early stage drug development including demonstrating efficacy; development time/cost and the regulatory approval process; the progress of our clinical trials; our ability to find and enter into agreements with potential partners; our ability to attract and retain key personnel; changing market conditions; inability of new manufacturers to produce acceptable batches of GMP in sufficient quantities; unexpected manufacturing defects; and other risks detailed from time-to-time in our ongoing quarterly filings, annual information forms, annual reports and annual filings with Canadian securities regulators and the United States Securities and Exchange Commission. Should one or more of these risks or uncertainties materialize, or should the assumptions set out in the section entitled “Risk Factors” in our filings with Canadian securities regulators and the United States Securities and Exchange Commission underlying those forward-looking statements prove incorrect, actual results may vary materially from those described herein.
These forward-looking statements are made as of the date of this press release and we do not intend, and do not assume any obligation, to update these forward-looking statements, except as required by law. We cannot assure you that such statements will prove to be accurate as actual results and future events could differ materially from those anticipated in such statements. Investors are cautioned that forward-looking statements are not guarantees of future performance and accordingly investors are cautioned not to put undue reliance on forward-looking statements due to the inherent uncertainty therein.
For further information, please contact
Aptose Biosciences Inc.
Susan Pietropaolo
Corporate Communications & Investor Relations
201-923-2049
spietropaolo@aptose.com
FAQ
When did Aptose Biosciences (APTOF) begin trading on the OTCQB Market?
What is Aptose Biosciences' (APTOF) main product in development?
What stock exchanges does Aptose Biosciences trade on?
What are the requirements for trading on the OTCQB Market?
